As of 10:31 AM on the 20th, Celltrion Healthcare is trading at 144,100 KRW, up 2.93% from the previous day. The trading volume is 1,325,040 shares, which is 27.37% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.
On January 18, researcher Han Byunghwa of Eugene Investment & Securities stated, "The stock price sharply dropped in the short term due to mixed views on the clinical results of Reciroona Injection. We believe the published clinical data is sufficient for emergency approval both domestically and internationally. Additionally, we consider that COVID-19 antibody treatments play an appropriate role in filling the gap left by vaccines. Pandemics caused by worsening climate crises are inevitable to recur periodically in the future. The know-how Celltrion Group has secured this time regarding the development, manufacturing, and sales of Reciroona Injection will be a key driver for being recognized as a global big pharma." He set the target price for Celltrion Healthcare at 190,000 KRW.
Over the past five days, individual investors have net purchased 224,676 shares of Celltrion Healthcare, while foreigners and institutions have net purchased 188,232 shares and net sold 416,596 shares, respectively.
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
